Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.
Metastatic Colorectal Cancer
DRUG: Regorafenib
Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria., 30 months
Percentage of total administrated dose over the planned dose accomplished in each arm., 30 months|Dose intensity during the whole treatment., 30 months|Dose intensity during first two cycles., 2 months|Disease control rate (DCR), 30 months|Progression-free survival (PFS), 30 months|Time to treatment failure (TTF), 30 months|Overall survival (OS), 30 months
The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.